A Pilot Study to Evaluate if Response to Infliximab or Adalimumab May be Regained with the Addition of an Immunomodulator
-
- STATUS
- Not Recruiting
Updated on 19 February 2024
Summary
The purpose of this study is to treat patients who have lost response to adalimumab or infliximab with an immunomodulator with the goal of eliminating the circulating antibodies to the anti-TNF and restoring efficacy.
Description
The purpose of this study is to treat patients who have lost response to adalimumab or infliximab with an immunomodulator with the goal of eliminating the circulating antibodies to the anti-TNF and restoring efficacy.
Details
| Condition | inflammatory bowel disease |
|---|---|
| Age | 100years or below |
| Clinical Study Identifier | TX5077 |
| Last Modified on | 19 February 2024 |
How understandable was the trial content above?
Hard to understand
Easy to understand
Similar trials to consider
Loading...
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.